I can't remember bta releasing a japanese inavir study and then they release a perceived bad study that just looks like the perameters were wrong. You really have to wonder why the heck bta would do this. I have left a call with mgmt to explain. This proyphaix study is in the scheme of things a non event.
But with the way the market is no surprise bta has gone down.
Ann: Phase III prophylaxis trial for CS-8958 , page-9
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)